FY2024 EPS Estimates for Journey Medical Cut by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Analysts at Roth Capital decreased their FY2024 earnings per share (EPS) estimates for shares of Journey Medical in a report issued on Monday, November 18th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($1.00) per share for the year, down from their previous estimate of ($0.93). The consensus estimate for Journey Medical’s current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.09 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

A number of other equities analysts have also recently commented on the company. Rodman & Renshaw began coverage on Journey Medical in a report on Thursday, August 22nd. They set a “buy” rating and a $9.00 price target for the company. Lake Street Capital initiated coverage on Journey Medical in a research note on Friday, September 6th. They set a “buy” rating and a $9.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.38.

Journey Medical Trading Down 2.2 %

DERM opened at $5.23 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical has a twelve month low of $2.85 and a twelve month high of $8.11. The company has a 50-day simple moving average of $5.63 and a 200 day simple moving average of $5.09.

Hedge Funds Weigh In On Journey Medical

A number of hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC increased its position in Journey Medical by 687.5% during the 1st quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock valued at $817,000 after purchasing an additional 194,389 shares during the period. PVG Asset Management Corp acquired a new stake in shares of Journey Medical during the second quarter worth $894,000. Cambridge Investment Research Advisors Inc. bought a new position in Journey Medical during the second quarter worth $1,664,000. TMD Wealth Management LLC bought a new position in Journey Medical during the second quarter worth $65,000. Finally, ORG Wealth Partners LLC acquired a new position in Journey Medical in the third quarter valued at $110,000. 7.25% of the stock is currently owned by institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.